Clear Cell Adenocarcinoma

An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)

Also Known As:

Networked: 297 relevant articles (14 outcomes, 36 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Anoxia (Hypoxia)
2.	Neoplasm Metastasis (Metastasis)
3.	Adenoma (Adenomas)
4.	Neoplasms (Cancer)
5.	Carcinoma (Carcinomatosis)

Experts

1.	Aoki, Daisuke: 14 articles (02/2016 - 09/2004)
2.	Mikami, Mikio: 9 articles (01/2015 - 12/2007)
3.	Suzuki, Nao: 8 articles (02/2010 - 09/2004)
4.	Takano, Masashi: 7 articles (06/2012 - 02/2008)
5.	Tsuda, Hiroshi: 7 articles (07/2010 - 11/2002)
6.	Miyazawa, Masaki: 6 articles (04/2014 - 12/2007)
7.	Yasuda, Masanori: 6 articles (04/2014 - 12/2007)
8.	Matsubara, Osamu: 6 articles (06/2012 - 07/2007)
9.	Yamamoto, Sohei: 6 articles (06/2012 - 07/2007)
10.	Tsuda, Hitoshi: 6 articles (06/2012 - 07/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Clear Cell Adenocarcinoma:

1.	Cisplatin (Platino)FDA LinkGeneric 12/01/2008 - "Since GPX3 suppression increased the cisplatin sensitivity of clear cell adenocarcinoma cells, GPX3 may be a candidate gene associated with the low cisplatin sensitivity of clear cell adenocarcinoma." 12/01/2008 - "GPX3 suppression by RNA interference increased cisplatin sensitivity 3.3-4.2-fold in 3 of the 4 clear cell adenocarcinoma cell lines. " 12/01/2008 - "Obtained candidate genes were suppressed by RNA interference and changes in the cisplatin sensitivity of clear cell adenocarcinoma cells were observed. " 09/01/1999 - "Remarkable suppressive effect of consecutive low-dose cisplatin therapy on advanced ovarian clear cell adenocarcinoma." 05/01/1989 - "A 60-year-old woman with recurrent stage II endometrial cancer (clear cell adenocarcinoma) was treated with combination chemotherapy containing cisplatin (CDDP). "
2.	irinotecan (Camptosar)FDA LinkGeneric 06/01/2005 - "The purpose of this study was to report the results of adjuvant CPT-11 and MMC combination chemotherapy (CPT-M) for ovarian clear cell adenocarcinoma (OCCA). " 01/01/2012 - "Irinotecan plus cisplatin therapy may effective for the clear cell adenocarcinoma. " 09/01/1999 - "CPT-11 plus cisplatin is feasible and has efficacy for ovarian clear cell adenocarcinoma. " 09/01/1999 - "We planned a pilot study of CPT-11 and cisplatin for the treatment of ovarian clear cell adenocarcinoma. " 09/01/1999 - "A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma."
3.	Sirolimus (Rapamycin)FDA Link 12/18/2007 - "The cell line HUOCA-II, which originates from the refractory ovarian clear cell adenocarcinoma, was treated with rapamycin. " 04/28/2011 - "This study was designed to clarify the mechanism of the mammalian target of rapamycin (mTOR)-hypoxia inducible factor-1 (HIF-1) pathway using the cultured cell strain derived from human ovarian clear cell adenocarcinoma (CCA). " 09/01/2013 - "Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial." 09/01/2013 - "Before setting into the clinical trial using a combination of mammalian target of rapamycin (mTOR) inhibitors (rapamycin and everolimus) and other anticancer drugs, this study was conducted to confirm the efficacy of the new therapeutic strategy for ovarian clear cell adenocarcinoma (CCA), which targeted mTOR-hypoxia-induced factor (HIF) signal transduction system. " 01/01/2013 - "Stathmin Regulates Hypoxia-Inducible Factor-1α Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma."
4.	Estrogens (Estrogen)FDA Link 05/01/1979 - "The importance of the mouse model for the study of the relevance of estrogen-induced, irreversible changes and other factors in the development of human clear cell adenocarcinomas in the vagina and cervix is stressed." 12/01/2011 - "Re-expression of estrogen receptor β inhibits the proliferation and migration of ovarian clear cell adenocarcinoma cells." 02/01/1976 - "However, a similar sequence of events must also be accepted to occur "spontaneously" since clear cell adenocarcinoma can develop in women without a history of maternal estrogens." 04/01/1998 - "Prenatal exposure to DES has been associated with several malformations in the lower genital tract, a higher prevalence of adenosis, and increased risk of clear cell adenocarcinoma, and estrogen-dependent tumors. " 06/14/2012 - "In utero exposure to a synthetic estrogen, diethylstilbestrol (DES), induces vaginal clear-cell adenocarcinoma in humans. "
5.	everolimusFDA Link 09/01/2013 - "Before setting into the clinical trial using a combination of mammalian target of rapamycin (mTOR) inhibitors (rapamycin and everolimus) and other anticancer drugs, this study was conducted to confirm the efficacy of the new therapeutic strategy for ovarian clear cell adenocarcinoma (CCA), which targeted mTOR-hypoxia-induced factor (HIF) signal transduction system. "
6.	taxaneIBA 02/15/2009 - "In this study, we investigated whether expression of these microtubule-associated factors affects the therapeutic efficacy of taxane-based chemotherapy in ovarian clear cell adenocarcinoma. " 02/15/2009 - "Estimated overall survival revealed a significant synergistic effect between taxane and beta-tubulin III in patients with ovarian clear cell adenocarcinoma. " 02/15/2009 - "Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma." 02/15/2009 - "Taxane-based chemotherapy was effective for patients with ovarian clear cell adenocarcinomas who were positive for beta-tubulin III but not for those who were negative for these proteins." 02/15/2009 - "We examined 94 surgically resected ovarian clear cell adenocarcinoma specimens from patients treated with taxane-containing regimens (n=44) and with taxane-free regimens (n=50), using immunohistochemistry to detect expression of beta-tubulin III, stathmin, and MAP4. "
7.	AntibodiesIBA 02/01/2006 - "With the antibodies against the betaA-subunit, and activin A, we observed positive immunoreactive staining in the cytoplasm of clear cell adenocarcinoma, whereas we did not observe any staining for the alpha-subunit of inhibin. " 04/01/1995 - "Clear cell adenocarcinoma of the female urethra showing positive staining with antibodies to prostate-specific antigen and prostatic acid phosphatase." 06/01/1995 - "The tumor cells were stained positively with antibodies to prostate specific antigen (PSA) and prostatic acid phosphatase (PAP), suggesting that the clear cell adenocarcinoma arises from the female paraurethral duct, rather than embryonic remnant." 04/01/1995 - "The tumor cells stained positively with antibodies to prostate-specific antigen and prostatic acid phosphatase, suggesting that the clear cell adenocarcinoma arises from the female paraurethral duct, rather than embryonic remnants." 04/01/2010 - "The following antibodies were not helpful in distinguishing nephrogenic adenoma-like clear cell adenocarcinoma from nephrogenic adenoma: CD10, estrogen receptor, p63, high-molecular-weight cytokeratin, and alpha-methylacyl coenzyme-A racemase. "
8.	Doxorubicin (Adriamycin)FDA LinkGeneric 07/01/2007 - "Our results suggest that adriamycin-related chemicals that are taken up via SLC22A16 may have the potential to be effective against clear-cell adenocarcinoma." 07/01/2015 - "A 53-year-old patient with recurrent ovarian clear cell adenocarcinoma developed fever (39°C) and cough on day 28 of liposomal doxorubicin chemotherapy, the 4th cycle of the 4th regimen since initial treatment. " 07/01/2001 - "In the 19 ovarian carcinomas examined, the mean Topo II alpha index (%) and the tumor cell growth inhibition rate (I.R.: %) for doxorubicin and etoposide in the clear cell adenocarcinomas [15.8, 21.4, 32.3] were all lower than in the endometrioid [33.9; p<0.001, 58.3, 61.9; p<0.05, respectively] and serous adenocarcinomas [43.6; p<0.001, 75.0, 79.8; p<0.01, respectively]. "
9.	TAC 101IBA 09/01/2004 - "Apoptosis occurred in all of the cell lines (except KF) in a concentration-dependent manner after exposure to TAC-101 and was markedly induced in RMG-I and RMG-II cells (derived from ovarian clear cell adenocarcinomas). " 09/01/2004 - "Oral TAC-101 shows potential as a novel antitumor agent for ovarian carcinoma, especially ovarian clear cell adenocarcinoma." 03/01/2008 - "These in vitro findings suggest that a combination of TAC-101 and cisplatin may be a potential new treatment for ovarian clear cell adenocarcinoma." 03/01/2008 - "TAC-101 (8 mg/kg/day orally for 21 days), cisplatin (7 mg/kg intravenously on day 1), or a combination of both drugs at the same dosages was administered to nude mice implanted subcutaneously with RMG-I or RMG-II clear cell adenocarcinoma cells. " 03/01/2008 - "A novel retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), induces apoptosis of ovarian clear cell adenocarcinoma. "
10.	CortactinIBA 03/01/2009 - "Thus, the expression of fascin-1, cortactin, and survivin may be helpful in evaluating the aggressiveness of ovarian mucinous, serous, and clear cell adenocarcinoma. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 08/01/1997 - "[Efficacy of chemotherapy for clear cell adenocarcinoma of the ovary]." 06/01/2014 - "Clear cell adenocarcinoma (CCA) of the ovary is highly resistant to chemotherapy. " 07/01/2010 - "Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary." 02/01/2010 - "Among them, clear cell adenocarcinoma (CCC) has a poor response to chemotherapy and poor prognosis compared with other histological types. " 01/01/2010 - "We present a case of metastatic clear cell adenocarcinoma of the bladder treated with chemotherapy."
2.	Radiotherapy 01/01/2002 - "Thus, radiotherapy may be effective for treatment of clear cell adenocarcinoma of the ovary." 12/01/2007 - "The aim of this study was to clarify the efficacy of postoperative whole abdominal radiotherapy (WAR) for ovarian clear cell adenocarcinoma (OCCA). " 11/01/2014 - "The aims of this study were to analyze patterns of recurrence in patients with ovarian clear cell adenocarcinoma (CCA) and to evaluate the role of pelvic radiotherapy (RT). " 11/01/2014 - "Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma." 12/01/2007 - "Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary."
3.	Brachytherapy 06/01/2015 - "High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra." 06/01/2015 - "Thirty-six year old male, case of primary clear cell adenocarcinoma of urethra who refused surgery, underwent cystoscopic assisted intraluminal HDR brachytherapy. " 10/01/2012 - "Clear cell adenocarcinoma of the female genital tract: long-term outcome and fertility aspects after brachytherapy aimed at a conservative treatment." 03/01/1998 - "The prognosis is not as good for patients treated for a clear cell adenocarcinoma of the vagina and/or the cervix who may have morphological and/ or functional anomalies of the genital tract, following exposure to diethylstilboestrol and brachytherapy (group 1). " 11/01/1996 - "Twelve magnetic resonance (MR) imaging studies were performed during intracavitary brachytherapy (10 initial studies and two during repeat brachytherapy) in 10 patients with clear cell adenocarcinoma (n = 9) or epithelioma (n = 1). "
4.	Combination Drug Therapy (Combination Chemotherapy) 10/01/2006 - "[Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma]." 10/01/2005 - "Patients with ovarian clear cell adenocarcinoma generally have a poor response to combination chemotherapy and have overall poorer prognosis than patients with other histologic types of ovarian cancer. " 10/01/2013 - "In conclusion, TC combination chemotherapy was well tolerated and generated a good response in a patient with recurrent ovarian clear cell adenocarcinoma who was receiving hemodialysis for chronic kidney disease." 11/01/1994 - "Clear cell adenocarcinoma of the vagina in a young female, treated by combination chemotherapy (local and systemic chemotherapy), complicated with chromosomal abnormality." 06/01/2005 - "The purpose of this study was to report the results of adjuvant CPT-11 and MMC combination chemotherapy (CPT-M) for ovarian clear cell adenocarcinoma (OCCA). "
5.	Heterologous Transplantation (Xenotransplantation) 07/01/2006 - "Furthermore, a xenograft model of human endometriosis was made with or without ovarian clear cell adenocarcinoma and cytokine production was investigated. " 02/01/2010 - "Furthermore, RNA interference studies with small interfering RNA (siRNA) were performed to assess the effect of POU6F1 on proliferation of xenograft tumors after injection of clear cell adenocarcinoma cells into nude mice. " 07/01/2006 - "Then xenograft models of human ovarian clear cell adenocarcinoma with or without human ectopic endometrium were created in severe combined immunodeficiency mice, and tumor growth was assessed from the wet weight and the bromodeoxyuridine uptake. "